Propofol TIVA versus TCI for anesthesia in patients with myasthenia gravis.

DOI: 10.36210/BerMedJ/epub1112019

Authors

Abstract

Myasthenia gravis (MG) is an autoimmune disease characterized by the formation of autoantibodies against nicotinic postsynaptic acetylcholine receptors of the motor end plate. The overall incidence of MG is 3-4:1,000,000, with a prevalence of 60-100 per 1,000,00 people. In addition to the primary acetylcholine receptor antibodies, receptor dysfunction due to drug interactions in the neuromuscular transmission disorder during anesthesia may also be a factor. The uncomplicated use of propofol has been demonstrated in individual cases in the literature.

propofol

Downloads

Published

2019-02-17 — Updated on 2025-01-29

How to Cite

Schedler, O., Grebe, D., Werner, J., Böttger, J., & Gellert, K. (2025). Propofol TIVA versus TCI for anesthesia in patients with myasthenia gravis.: DOI: 10.36210/BerMedJ/epub1112019. Berlin Medical Journal, 1(1). Retrieved from https://bmjs.me/index.php/BMJ/article/view/37

Issue

Vol. 1 No. 1 (2019): BerMedJ-Berlin Medical Journal

Section

original

License

Copyright (c) 2019 Olaf Schedler; Dirk Grebe, Jörg Werner, Joachim Böttger, Klaus Gellert

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.